The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes.
作者信息
Kristensen Daniel Tuyet, Øvlisen Andreas Kiesbye, El-Galaly Tarec Christoffer, Roug Anne Stidsholt
机构信息
Department of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
出版信息
Blood Adv. 2024 Nov 26;8(22):5932-5934. doi: 10.1182/bloodadvances.2024014173.
Abstract
摘要
相似文献
1
The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes.在无糖尿病登记标记的患者中使用二甲双胍与骨髓增殖性肿瘤风险
Blood Adv. 2024 Nov 26;8(22):5932-5934. doi: 10.1182/bloodadvances.2024014173.
2
Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial.二甲双胍和胰岛素治疗妊娠期糖尿病：对炎症标志物和 IGF 结合蛋白-1 的影响 - 一项随机对照试验的二次分析。
BMC Pregnancy Childbirth. 2020 Jul 11;20(1):401. doi: 10.1186/s12884-020-03077-6.
3
Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study.二甲双胍的使用与骨髓增生性肿瘤风险：一项丹麦基于人群的病例对照研究。
Blood Adv. 2024 Aug 27;8(16):4478-4485. doi: 10.1182/bloodadvances.2023012266.
4
Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms.二甲双胍在 JAK2 阳性骨髓增生性肿瘤中发挥多靶点抗白血病活性。
Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.
5
Centratherum anthelminticum seeds administration improved risk factor markers in metformin treated type 2 diabetic patients.穿心莲种子给药改善了二甲双胍治疗的 2 型糖尿病患者的风险因素标志物。
Pak J Pharm Sci. 2023 Nov;36(6(Special)):1869-1873.
6
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.罗格列酮和二甲双胍对炎症标志物及脂肪因子的影响：白细胞介素-18降低是2型糖尿病患者稳态模型评估-胰岛素抵抗指数改善的独立因素。
Clin Endocrinol (Oxf). 2007 Feb;66(2):282-9. doi: 10.1111/j.1365-2265.2006.02723.x.
7
Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.二甲双胍可降低肝癌切除术后肝癌复发的风险。
Liver Int. 2017 Mar;37(3):434-441. doi: 10.1111/liv.13280. Epub 2016 Nov 13.
8
Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.二甲双胍对新诊断 2 型糖尿病患者氧化应激和抗氧化储备标志物的影响：一项随机临床试验。
Clin Nutr. 2013 Apr;32(2):179-85. doi: 10.1016/j.clnu.2012.08.006. Epub 2012 Aug 21.
9
Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?2 型糖尿病患者中意义未明的单克隆丙种球蛋白病向多发性骨髓瘤进展减少：二甲双胍会否永远带来惊喜？
Adv Ther. 2022 Jun;39(6):2283-2286. doi: 10.1007/s12325-022-02125-1. Epub 2022 Mar 28.
10
Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials.比较二甲双胍与胰岛素治疗的既往妊娠糖尿病女性的葡萄糖代谢和人体测量学：两项随机试验的 9 年随访。
Acta Obstet Gynecol Scand. 2022 May;101(5):514-523. doi: 10.1111/aogs.14343. Epub 2022 Mar 11.
本文引用的文献
1
Diabetes mellitus, metformin, and the risk of MPN.糖尿病、二甲双胍与骨髓增殖性肿瘤风险
Blood Adv. 2024 Nov 26;8(22):5929-5931. doi: 10.1182/bloodadvances.2024013772.
2
Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study.二甲双胍的使用与骨髓增生性肿瘤风险：一项丹麦基于人群的病例对照研究。
Blood Adv. 2024 Aug 27;8(16):4478-4485. doi: 10.1182/bloodadvances.2023012266.
3
Repurposing Metformin in hematologic tumor: State of art.在血液肿瘤中重新利用二甲双胍：现状。
Curr Probl Cancer. 2023 Aug;47(4):100972. doi: 10.1016/j.currproblcancer.2023.100972. Epub 2023 Jun 20.
4
Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study.使用他汀类药物与骨髓增生性肿瘤风险：一项丹麦全国范围内的病例对照研究。
Blood Adv. 2023 Jul 25;7(14):3450-3457. doi: 10.1182/bloodadvances.2023009784.
5
Data Resource Profile: The Danish National Prescription Registry.数据资源简介：丹麦国家处方登记处
Int J Epidemiol. 2017 Jun 1;46(3):798-798f. doi: 10.1093/ije/dyw213.
6
The Danish National Patient Registry: a review of content, data quality, and research potential.丹麦国家患者登记处：内容、数据质量及研究潜力综述
Clin Epidemiol. 2015 Nov 17;7:449-90. doi: 10.2147/CLEP.S91125. eCollection 2015.
7
The Danish National Prescription Registry.丹麦国家处方登记处。
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41. doi: 10.1177/1403494810394717.
8
The Danish National Patient Register.丹麦国家患者登记处。
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. doi: 10.1177/1403494811401482.
Zotero 插件